Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes
NCT03883412Phase 4Recruiting
- Sponsor
- University of Virginia
- Start
- Feb 2019
- Primary completion
- Jun 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by University of Virginia. Primary endpoint: Microvascular Blood Volume at 16 weeks. Started Feb 2019; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03883412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03883412.